Press Releases

Date Title
July 16, 2019
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Full enrollment expected to occur in calendar Q4 2019 CRANBURY, N.J. , July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate
June 3, 2019
Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010
CRANBURY, N.J. , June 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular
May 15, 2019
Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019
CRANBURY, N.J. , May 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter ended March 31, 2019 . Recent Highlights: FDA acceptance and activation of the IND application for
April 26, 2019
Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development
CRANBURY, N.J. , April 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age
April 10, 2019
Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
CRANBURY, N.J. , April 10, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common
April 1, 2019
Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
Enrollment of U.S. patients in the ONS-5010-002 Phase 3 clinical trial expected to be initiated in calendar Q2 2019 CRANBURY, N.J. , April 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the U.S. Food and Drug Administration ( FDA ) acceptance
March 15, 2019
Outlook Therapeutics Announces Reverse Stock Split
CRANBURY, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 reverse stock split of the Company’s common stock, which became effective this morning immediately upon the filing by the
March 5, 2019
Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements
CRANBURY, N.J. , March 05, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today that the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing
March 1, 2019
Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA
CRANBURY, N.J. , March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) for ONS-5010.
February 14, 2019
Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019
CRANBURY, N.J. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter ended December 31, 2018 . Recent Highlights: Reached 75% enrollment completion in ONS-5010-001, a Phase 3
Displaying 1 - 10 of 62